The first study of its kind reports that patients should keep taking well-known heart medications.
Patients with heart conditions that require angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) can safely keep taking them if hospitalized with coronavirus disease 2019 (COVID-19), based on findings from the first randomized trial to examine this issue.
Data from the BRACE CORONA trial, presented today during the European Society of Cardiology 2020 Congress, show no difference in outcomes between patients who kept taking their ACE inhibitors or ARBs and those who stopped taking them for 30 days following a COVID-19 diagnosis.
Investigators found that the average number of days alive and out of hospital was 21.9 for patients who stopped ACE inhibitors/ARBs and 22.9 for patients who continued these medications, for a mean ratio of 0.95 (95% CI, 0.90-1.01; P = .09). The average difference in clinical status at 30 days between groups was -1.1 days (95% CI, -2.33 to 0.17).
“This is the first randomized data assessing the role of continuing versus stopping ACE inhibitors and ARBs in patients with COVID-19,” said principal investigator Renato Lopes, MD, PhD, of Duke Clinical Research Institute, Durham, North Carolina. “Because these data indicate that there is no clinical benefit from routinely suspending these medications in hospitalized patients with mild to moderate COVID-19, they should be generally continued for those with an indication.”
BRACE CORONA randomized 659 patients at 29 sites in Brazil, which has been hit hard by the pandemic. The trial examined the conflicting theories that have stymied clinicians since the pandemic began.
On the one hand, early links between COVID-19 deaths and hypertension worried public health clinicians, due to associations between angiotensin-converting enzyme 2 (ACE2) and SARS-CoV-2. ACE2 was seen as a port of entry for the virus that causes COVID-19, and thus could make COVID-19 more dangerous in some patients. Yet other evidence suggested that renin-angiotensin-aldosterone system inhibitors could actually reduce acute lung damage from COVID-19.
Patients who were using more than 3 antihypertensive drugs, or sacubitril/valsartan, or who were hemodynamically unstable at hospital admission were excluded from the study.
The trial also examined several secondary end points, Lopes said, including myocardial infarction and stroke and how far the disease had progressed, as measured by whether a patient was intubated or in the intensive care unit. “Basically, the results are very consistent,” he said. “We do not see any significant difference between treatment strategies in any of the key secondary end points that were also assessed in the trial.”
Lopes said the results confirm early guidance from professional societies to keep patients on their medication in most cases. Subgroup analyses, which will examine whether there are any differences by age or obesity status or other factors, will be forthcoming.
Reference
Lopes R, on behalf of the BRACE CORONA Investigators. Continuing versus suspending ACE inhibitors and ARBs: impact of adverse outcomes in hospitalized patients with COVID-19—the BRACE CORONA Trial. Presented at the European Society of Cardiology 2020 Congress, September 1, 2020.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More